Drug resistance associated properties of blasts subpopulations with different CD34 expression in childhood acute lymphoblastic leukemia (ALL)

• Published in: Experimental Oncology
• Date: 2011
• Main Authors: Shman, T.V., Fedasenka, U.U., Savitski, V.P., Kustanovich, A.M., Aleinikova, O.V.
• Format: Article
• Language: English
• Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2011
• Subjects: Original contributions
• Online Access: https://nasplib.isofts.kiev.ua/handle/123456789/138658
• Journal Title: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Cite this: Drug resistance associated properties of blasts subpopulations with different CD34 expression in childhood acute lymphoblastic leukemia (ALL) / T.V. Shman, U.U. Fedasenka, V.P. Savitski, A.M. Kustanovich, O.V. Aleinikova // Experimental Oncology. — 2011. — Т. 33, № 3. — С. 145-149. — Бібліогр.: 35 назв. — англ.

Aim: The objective of this study was to investigate expression of drug resistance associated genes in CD34+ and CD34- leukemic subpopulations in childhood acute lymphoblastic leukemia (ALL). Methods: ALL samples with heterogeneous CD34 expression were separated into CD34-positive and CD34-negative subpopulations and mRNA levels of MDR1, LRP , BCRP and BCL-2 genes were compared. Results: BCL-2 gene expression levels did not differ significantly between CD34+ vs CD34− subpopulations in most analyzed ALL cases. Oppositely, MDR1 gene had >two-fold differences in expression levels between subpopulations in the majority of ALL cases. In T-lineage ALL CD34− fractions had increased level of BCRP and LRP genes in comparison with CD34+ ones whereas in most of B-lineage ALL expression of these genes did not differ. Conclusion: It was not found the unique pattern of resistance related genes expression in CD34+ vs CD34− subpopulations. However, in majority of studied pediatric ALL cases with CD34 heterogeneous expression one of subpopulations (positive or negative) could have an advantage for survival through elevated expression of drug resistance related genes.